Have a personal or library account? Click to login
The Importance of Identification of M-BCRABL Oncogene and JAK2V617F Mutation in Myeloproliferative Neoplasms Cover

The Importance of Identification of M-BCRABL Oncogene and JAK2V617F Mutation in Myeloproliferative Neoplasms

Acta Marisiensis - Seria Medica
Volume 60 (2014): Issue 2 (April 2014)
By: Annamária Szántó,  Zsuzsanna Pap,  Z Pávai,  I Benedek,  Judit Beáta Köpeczi,  Aliz- Beáta Tunyogi,  Emőke Horváth and  Benedek Erzsébet Lázár  
Open Access
|Apr 2014

References

  1. 1. Tefferi A, Thiele J, Vardiman J. The 2008 World Health Organization Classifi cation System for Myeloproliferative Neoplasms-order out of Chaos. Cancer. 2009:3842-3847.10.1002/cncr.24440
    Search in Google Scholar
  2. 2. Vardiman J, Thiele J, Daniel A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.10.1182/blood-2009-03-209262
    Search in Google Scholar
  3. 3. Koopmans SM, van Marion AMW, Schouten HC. Myeloproliferative neoplasia: a review of clinical criteria and treatment. Neth J Med. 2012;70(4):159-165.
    Search in Google Scholar
  4. 4. Pane F, Intrieri M, Quintarelli C, et al. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene. 2002;21(56):8652-8667.10.1038/sj.onc.1206094
    Search in Google Scholar
  5. 5. McLornan D, Percy M, McMullin M. JAK2V617F: A Single Mutation in the Myeloproliferative Group of Disorders. Ulster Med J. 2006;75(2):112-119.
    Search in Google Scholar
  6. 6. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357.10.1038/sj.leu.2403135
    Search in Google Scholar
  7. 7. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program. Leukemia. 2003;17(12):2474-2486.10.1038/sj.leu.2403136
    Search in Google Scholar
  8. 8. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.10.1016/S0140-6736(05)71142-9
    Search in Google Scholar
  9. 9. Hehlmann R, Grimwade D, Simonsson B, et al. The European LeukemiaNet: achievements and perspectives. Haematologica. 2011;96(1):156-162.10.3324/haematol.2010.032979301278021048032
    Search in Google Scholar
  10. 10. Szántó A, Pap Z, Benedek I, et al. Monitoring M-BCR-ABL expression level in CML patients by RQ-PCR: experience of a single Center. Rom J Morphol Embryol. 2013;54(1):37-42.
    Search in Google Scholar
  11. 11. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-6051.10.1200/JCO.2009.25.0779497910019884523
    Search in Google Scholar
  12. 12. Tefferi A, Vardiman JW. Classifi cation and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14-22.10.1038/sj.leu.240495517882280
    Search in Google Scholar
  13. 13. Schnittger S, Bacher U, Eder Ch, et al. Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workfl ow. Haematologica. 2012;97(10):1582-1585.10.3324/haematol.2012.064683348756022511494
    Search in Google Scholar
  14. 14. Scott ML, Tong W, Ross LL, et al. JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. N Engl J Med. 2007;356(5):459-468.10.1056/NEJMoa065202287383417267906
    Search in Google Scholar
  15. 15. Bojko P, Abenhardt W, Schnittger S, Haferlach T. Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease. Onkologie. 2009;32(4):191-195.
    Search in Google Scholar
  16. 16. Cho YU, Chi HS, Lee EH, et al. Comparison of clinicopathologic fi ndings according to JAK2 V617F mutation in patients with essential thrombocythemia. Int J Hematol. 2009;89(1):39-44.10.1007/s12185-008-0222-019093167
    Search in Google Scholar
  17. 17. Ha JS, Kim YK, Jung SI, Jung HR, Chung IS. Correlations between Janus Kinase 2 V617F Allele Burdens and Clinicohematologic Parameters in Myeloproliferative Neoplasms. Ann Lab Med. 2012;32:385-391.10.3343/alm.2012.32.6.385348693123130336
    Search in Google Scholar
  18. 18. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G_T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome- negative CML, and megakaryocytic leukemia. Blood. 2005;106(10): 3370-3373.10.1182/blood-2005-05-1800189506516037387
    Search in Google Scholar
  19. 19. Pich A, Riera L, Sismondi F, et al. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol. 2009;62(9):798-801.10.1136/jcp.2009.06590419734476
    Search in Google Scholar
  20. 20. Hussein K, Bock O, Theophile K, et al. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia. 2008;22:1059-1062.10.1038/sj.leu.240499317972958
    Search in Google Scholar
  21. 21. Inami M, Inokuchi K, Okabe M, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia. 2007;21:1103-1104.10.1038/sj.leu.240459117301812
    Search in Google Scholar
  22. 22. Cappetta M, Perez V, Zubillaga MN, et al. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in fi ve patients with myeloproliferative neoplasm at diagnosis. Int J Lab Hematol. 2013;35:e4- e5. 10.1111/ijlh.1201023062104
    Search in Google Scholar
DOI: https://doi.org/10.2478/amma-2014-0010 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Journal RSS Feed
Language: English
Page range: 44 - 48
Submitted on: Apr 12, 2013
Accepted on: Mar 31, 2014
Published on: Apr 25, 2014
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
myeloproliferative neoplasms,
JAK2V617F mutation,
M-BCR-ABL oncogene
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other

© 2014 Annamária Szántó, Zsuzsanna Pap, Z Pávai, I Benedek, Judit Beáta Köpeczi, Aliz- Beáta Tunyogi, Emőke Horváth, Benedek Erzsébet Lázár, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 60 (2014): Issue 2 (April 2014)Next article